Kailera Therapeutics Appoints Jamie Coleman as Chief Commercial Officer

Appointment:
Jamie Coleman, former U.S. Brand Leader for Zepbound at Eli Lilly, has been appointed as Chief Commercial Officer at Kailera Therapeutics1.

Role:
Coleman will establish and execute Kailera's overall commercial strategy for its advanced clinical-stage product candidates for obesity and related conditions1.

Background:
Coleman has nearly 25 years of experience in leading transformative, global healthcare brands, including roles at Eli Lilly, Pfizer, and ZS Associates1.

Previous Achievements:
Coleman successfully launched Zepbound, a treatment for obesity, and led global brand strategies for Trulicity (type 2 diabetes) and Jardiance (diabetes market)1.

Company Overview:
Kailera Therapeutics is a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for obesity and related conditions13.

Product Pipeline:
Kailera's most advanced program, KAI-9531, is an injectable GLP-1/GIP receptor dual agonist that has shown positive results in Phase 2 trials in obesity and type 2 diabetes in China3.

Sources:

1. https://www.globenewswire.com/news-release/2025/01/27/3015512/0/en/Kailera-Therapeutics-Appoints-Jamie-Coleman-as-Chief-Commercial-Officer.html

3. https://finance.yahoo.com/news/kailera-therapeutics-emerges-stealth-400m-115004559.html